<DOC>
	<DOCNO>NCT00477113</DOCNO>
	<brief_summary>The Primary objective study determine incidence pattern serious infection , malignancy , serious adverse event ( SAE ) participants multiple sclerosis ( MS ) treat Tysabri ( natalizumab ) .</brief_summary>
	<brief_title>TYSABRI Global Observational Program Safety</brief_title>
	<detailed_description>The TYSABRI Global Observational Program Safety ( TYGRIS ) safety observational cohort program design obtain long-term safety data multiple sclerosis ( MS ) participant treat natalizumab clinical practice set United States Canada .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key MS patient US Canada receive TYSABRI standard clinical care less equal 3 infusion eligible participate TYGRIS . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>natalizumab</keyword>
	<keyword>MS</keyword>
	<keyword>Tysabri</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>TYGRIS</keyword>
</DOC>